<DOC>
	<DOCNO>NCT01415401</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability change AZARGA® prior brimonidine 0.2 % /timolol 0.5 % fix combination ( COMBIGAN® ) therapy patient open-angle glaucoma ocular hypertension uncontrolled intraocular pressure ( IOP ) .</brief_summary>
	<brief_title>Efficacy Tolerability AZARGA® Replacement Therapy Patients COMBIGAN® Therapy Canada</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<criteria>Willing sign Informed Consent form . Clinical diagnosis ocular hypertension , exfoliative openangle pigment dispersion glaucoma least one eye ( study eye ) . Be stable IOP lower regimen within 30 day Screening Visit . IOP consider safe , eye , way assure clinical stability vision optic nerve throughout study period . Willing discontinue use COMBIGAN® prior receive study drug Visit 1 . IOP 19 35 mmHg least one eye ( would study eye ) brimonidine/timolol fix combination therapy . Best correct visual acuity 6/60 ( 20/200 Snellen , 1.0 logMAR ) good eye . Willing follow instruction able attend require study visit . Other protocoldefined inclusion criterion may apply . Known history hypersensitivity component preparation use study . Presence primary secondary glaucoma list inclusion criterion # 2 . History ocular herpes simplex . Abnormality prevent reliable applanation tonometry . Corneal dystrophy . Concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye . Blepharitis nonclinically significant conjunctival injection allow . Intraocular conventional surgery laser surgery study eye ( ) less 3 month prior Screening Visit . Risk visual field visual acuity worsen consequence participation study , investigator 's best judgment . Progressive retinal optic nerve disease cause . Women childbearing potential use reliable mean birth control least 1 month prior Screening/Baseline Visit . Pregnant lactating . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Intraocular pressure ( IOP )</keyword>
	<keyword>Open angle glaucoma</keyword>
	<keyword>Pigment dispersion glaucoma</keyword>
	<keyword>Pigmentary</keyword>
</DOC>